SCHEMBL2908119

SCHEMBL2908119

COc1ccc(N(Cc2cccnc2)c2ccc(-c3nn[nH]n3)cc2)nc1O[C@@H]1CCOC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.36
CHEK1 O14757 1/20 0.35
SYK P43405 2/20 0.34
ALDH1A1 P00352 2/20 0.34
PDE4D Q08499 4/20 0.34
PDE4A P27815 4/20 0.34
PDE4B Q07343 3/20 0.34
PDE4C Q08493 3/20 0.34
FGFR3 P22607 2/20 0.33
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33
FGFR4 P22455 1/20 0.33
KDR P35968 1/20 0.33
CYP2A6 P11509 1/20 0.33
TAS2R14 Q9NYV8 1/20 0.33
RXRA P19793 1/20 0.32
AURKA O14965 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
GLA P06280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2908190 0.85 PDE4D (0.42) ALDH1A1PDE4DPDE4APDE4BPDE4C
SCHEMBL2905397 0.82 PDE4A (0.34) CHEK1SYKPDE4DPDE4APDE4B
SCHEMBL2904815 0.80 PDE4B (0.38) CHEK1ALDH1A1PDE4DPDE4APDE4B
SCHEMBL2902489 0.79 PDE4D (0.44) ALDH1A1PDE4DPDE4APDE4BPDE4C
SCHEMBL2910468 0.79 PDE4D (0.44) ALDH1A1PDE4DPDE4APDE4BPDE4C
SCHEMBL1157355 0.78 PDE4A (0.51) XDHALDH1A1PDE4DPDE4APDE4B
SCHEMBL2908116 0.76 AURKA (0.36) XDHCHEK1SYKALDH1A1CYP2A6
SCHEMBL2902373 0.76 AURKA (0.36) XDHCHEK1SYKALDH1A1CYP2A6
SCHEMBL2901842 0.76 PDE4D (0.38) CHEK1SYKPDE4DPDE4APDE4B
SCHEMBL2901989 0.76 PDE4D (0.42) SYKPDE4DPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B XDH 238/4885CHEK1 3252/4885SYK 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.